Role of CD28 in acute graft-versus-host disease

Blood

Volumn 92, Issue 8, 1998, Pages 2963-2970

  Yu, Xue Zhong ^b   Martin, Paul J ^b   Anasetti, Claudio ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0032532609     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2963     Document Type: Article

References (35)

1. Ferrara JL, Deeg HJ, Burakoff SJ: Graft-vs.-host disease. New York, NY, Marcel Dekker, 1996
2. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
3. Lenschow DJ, Walunas TL, Bluestone J: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14, 233, 1996
4. Brunet JF, Denizot F, Luciani MF, Roux-Dosetto M, Suzan M, Mattei MG, Golstein P: A new member of the immunoglobulin superfamily: CTLA-4. Nature 328:267, 1987
5. Lenschow DJ, Su GH, Zuckerman LA, Nabavi CL, Jellis CL, Gray GS, Miller J, Bluestone JA: Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 90:11054, 1993
6. Bluestone JA: Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 158:1989, 1997
7. Thompson CB, Allison JP: The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445, 1997
8. Perez VL, Parijs LV, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411, 1997
9. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177:165, 1993
10. Gimmi CD, Freeman GJ, Gribben JG, Gray GS, Nadler LM: Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586, 1993
11. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792, 1992
12. Lenschow DJ, Zen Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 257:789, 1992
13. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei R-Q, Gibson ML, Zheng X-G, Myrdal S, Gordon D, Bailey T, Boling SF, Thompson CB: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 89:11102, 1992
14. Lin H, Boiling SF, Linsley PS, Wei R-Q, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor-specific transfusion. J Exp Med 178:1801, 1993
15. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockage of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83:3815, 1994
16. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58:602, 1994
17. Hakim FT, Cepeda R, Gray GS, June CH, Abe R: Acute graft-versus-host reaction can be aborted by blockade of costimulation molecules. J Immunol 155:1757, 1995
18. + T cells. J Immunol 157:3250, 1996
19. Via CS, Rus V, Nguyen P, Linsely PS, Gause WC: Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development. J Immunol 157:4258, 1996
20. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW: Differential T cell costimulatory requirements in CD28 deficient mice. Science 261:609, 1993
21. Speiser DE, Bachmann MF, Shahinian A, Mak TW, Ohashi PA: Acute graft-versus-host disease without costimulation via CD28. Transplantation 63:1042, 1997
22. Martin PJ, Akatsuda Y, Hahne M, Sale G: Involvement of donor T cell cytotoxic effector mechanisms in preventing allogenic marrow graft rejection. Blood (in press)
23. Hakim FT, Sharrow SO, Payne S, Shearer GM: Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J Immunol 146:2108, 1991
24. Hakim FT, Pluznik DH, Shearer GM: Factors contributing to the decrease in Concanavalin A-induced colony-stimulating factors in acute suppressive graft-versus-host disorder. Transplantation 49:781, 1990
25. Hurtenbach U, Shearer GM: Analysis of murine T lymphocyte markers during the early phases of GvH-associated suppression of cytotoxic T lymphocyte responses. J Immunol 130:1561, 1983
26. Sprent J, Korngold R: Murine models for graft-versus-host disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell Scientific, 1995, p 220
27. Vallera DA, Taylor PA, Sprent J, Blazar BR: The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249, 1994
28. Piguet PF, Grau B, Allet B, Vassalli P: Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166:1280, 1987
29. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JL: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915, 1991
30. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB: Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H2-incompatible transplanted SCID mice. Blood 83:2360, 1994
31. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR: Interleukin-1 or tumor necrosis factor-antagonists do not inhibit graft-vesus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60:1371, 1995
32. Cai Z, Sprent J: Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J Exp Med 183:2247, 1996
33. Kundig TM, Shahinian A, Kawai K, Mittrucker H-W, Sebzda E, Bahmann MF, Mak TW, Ohashi PS: Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5:41, 1996
34. Bachmann MF, Mckall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW, Ohashi PS: Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7:549, 1997
35. Green JM, Noel PJ, Sperling AI, Walunas TL, Sperling AI, Gray GS, Bluestone JA, Thompson CB: Absence of B7-dependent responses in CD28-dificient mice. Immunity 1:501, 1994